

References

I-218

1. Ataga KI, Kutlar A, Kanter J, et al. Crizanlizumab for the prevention of pain crises in sickle cell disease. *NEJM*.2017;376:429-439.
2. Yawn BP and John-Sowah J. Management of sickle cell disease: recommendations from the 2014 expert panel report. *Am Fam Physician*.2015;92(12):1069-1076.
3. Micromedex DrugDex Compendium® 2024. Crizanlizumab.
4. Clinical Pharmacology Compendia™ 2024. Tampa FL: Gold Standard, Inc. Crizanlizumab-tmca.
5. Adakveo® (crizanlizumab-tmca) injection, for intravenous use [package insert]. Novartis Pharmaceuticals Corp. East Hanover, NJ. Revised 09/2022.
6. MCG™ Care Guidelines, 22nd edition, 2018, Home Infusion Therapy, CMT: CMT-0009(SR).
7. Crizanlizumab-tmca In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated September 23, 2023.